PLIANT THERAPEUTICS INC

Company Overview

Pliant Therapeutics is a late‑stage biotechnology company focused on small‑molecule and antibody therapies that inhibit integrin‑mediated activation of TGF‑β to treat fibrosis and related diseases. Its lead candidate, bexotegrast (oral αvβ6/αvβ1 inhibitor), showed early FVC efficacy signals but the global BEACON‑IPF Phase 2b was discontinued after a DSMB review identified an imbalance in unadjudicated IPF‑related adverse events; oncology and neuromuscular programs (PLN‑101095 and PLN‑101325) remain in early clinical development. The company operates an asset‑light model with in‑house discovery/translational capabilities, outsourced CMO manufacturing, >300 pending patent applications and a material need to manage cash runway amid widening R&D losses (net losses expanded and cash was $264.4M at 6/30/2025).

Executive Compensation Practices

Compensation at Pliant is likely driven heavily by clinical and regulatory milestones (e.g., DSMB readouts, cohort data, IND/CTA approvals), patent and partnering/licensing events, and preservation of cash runway; the discontinuation of BEACON‑IPF and a May 2025 restructuring will push boards to emphasize cost control and retention. Given persistent net losses and the need for future financing, pay packages in this biotech typically rely on equity‑linked incentives (stock options, RSUs, milestone‑vesting awards) to conserve cash while aligning management with long‑term value creation tied to clinical outcomes. The amended Oxford term loan and limited access to additional tranches tied to program progress increase the chance that the board will apply strict performance conditions, clawbacks or reduced cash bonuses, and implement one‑time retention or restructuring awards to hold key scientific executives.

Insider Trading Considerations

Insider trading patterns at Pliant will concentrate around clinical inflection points: DSMB communications, release/ adjudication of BEACON data, Phase 1 cohort readouts for PLN‑101095, and regulatory/partnering announcements — all of which are material and can move the stock. Because management and senior scientists hold equity compensation, expect routine option exercises and occasional sell‑to‑cover tax transactions; however, any open market sales close to material trial information will draw regulatory and investor scrutiny and should generally be governed by blackout windows and documented 10b5‑1 plans. Additional constraints may arise from lender covenants or financings (which can restrict transfers) and from heightened disclosure obligations under Section 16 and FDA‑sensitive information flow, so trades by insiders will often be clustered in pre‑planned windows following public disclosures.